Clinical Trials · NCT04591626
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 291
- Start date
- Dec 2020
- Locations
- 27 sites, China
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)